Abstract: Radioimmuntherapy (RIT) wasone of the most important progresses in the field of cancer therapy over thepast 20 years. It has been successfully appied in the treatment of blood systemtumors such as NHL. For the utilization of RIT in therapy of solid tumors,however, development of more effective monoclonal antibodies, labeling methodsand so on are needed. The current status of radionuclides, monoclonalantibodies and drugs commonly used in the RIT were briefly reviewed.